GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DCCR (diazoxide choline)

Company
Soleno Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Trial details
  • Withdrawn NCT NCT00901823

    Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline

    Not yet reported Essentialis, Inc. Est. completion 2011-03 Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Withdrawn NCT NCT00973271

    Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

    Not yet reported Essentialis, Inc. Est. completion 2011-12 Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT01211847

    Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

    Not yet reported Essentialis, Inc. 44 participants Est. completion 2011-12 Stand-alone
    Other conditions: Hypertriglyceridemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01211860

    Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

    Not yet reported Essentialis, Inc. 9 participants Est. completion 2010-11 1 site Stand-alone
    Other conditions: Hypertriglyceridmia
    View official trial listing →
  • Completed NCT NCT02034071

    Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

    Not yet reported, Not yet reported Essentialis, Inc. 13 participants Est. completion 2015-05 1 site Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Status unknown NCT NCT02893618

    A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

    Not yet reported Essentialis, Inc. 32 participants Est. completion 2017-12 Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT03440814

    A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

    Not yet reported Soleno Therapeutics, Inc. 127 participants Est. completion 2020-05-01 29 sites Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT03714373

    Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

    Not yet reported Soleno Therapeutics, Inc. 115 participants Est. completion 2023-08-17 28 sites Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Withdrawn NCT NCT04086810

    An Open-Label Study of DCCR Tablet in Patients With PWS

    Not yet reported Soleno Therapeutics, Inc. Est. completion 2019-10 Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Withdrawn NCT NCT05532020

    An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

    Not yet reported Soleno Therapeutics, Inc. Est. completion 2024-03 Stand-alone
    Other conditions: SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant), SIM1 Deficiency Obesity
    View official trial listing →
  • Completed NCT NCT05701774

    Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

    Not yet reported Soleno Therapeutics, Inc. 77 participants Est. completion 2026-04-29 22 sites Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Enrolling by invitation NCT NCT07450664

    Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

    Soleno Therapeutics, Inc. 200 participants Est. completion 2028-03-02 24 sites
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: DCCR (diazoxide choline), DCCR (diazoxide choline) extended-release tablets, DCCR

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.